Flecainide is Contraindicated in Patients with Coronary Artery Disease
Flecainide should be avoided in patients with ischemic heart disease (active ischemia or history of myocardial infarction) according to current guidelines 1. This contraindication stems from the landmark CAST trial, which demonstrated increased mortality when flecainide was used to suppress ventricular ectopy in post-MI patients 2.
Absolute Contraindications for Flecainide
The following conditions preclude flecainide use 1:
- Active ischemia or history of myocardial infarction
- Left ventricular systolic dysfunction (LVEF < 40%)
- Significant left ventricular hypertrophy
- Advanced AV block (second- or third-degree) without pacemaker 3
- Severe renal impairment (CrCl < 35 mL/min)
- Heart failure (NYHA class II-IV or LVEF < 30%) 3
Screening Requirements Before Initiating Flecainide
For patients over 50 years of age or those with significant atherosclerotic risk factors, a formal ischemia assessment (e.g., stress test) should be performed before starting flecainide 1. This is critical because the drug's proarrhythmic risk—specifically monomorphic ventricular tachycardia, not torsades de pointes—is highest in patients with structural heart disease, ventricular scar tissue, or conduction delays 2.
Emerging Evidence: A Nuanced Picture
While guidelines maintain strict contraindications, recent observational data suggest a more complex reality. Multiple retrospective studies 4, 5 have shown that flecainide use in stable, nonobstructive CAD without prior MI and with preserved LV function was not associated with increased mortality or ventricular arrhythmias. A 2026 systematic review 6 found no excess ventricular arrhythmia risk across structural heart disease populations, including CAD subgroups, though substantial heterogeneity existed.
However, these are hypothesis-generating studies only—they do not override current guideline recommendations 1, 7. The FDA label explicitly warns against use in patients with coronary artery disease or pre-existing heart failure 3.
Practical Algorithm for Decision-Making
- Screen for absolute contraindications (prior MI, active ischemia, LVEF < 40%, significant LVH)
- If patient is > 50 years or has atherosclerotic risk factors: Perform stress test to exclude ischemia 1
- If ischemia is present or history of MI exists: Do NOT use flecainide—choose amiodarone or dronedarone instead 1, 8
- If patient has stable CAD without ischemia and normal LV function: Current guidelines still recommend avoiding flecainide 1, 7, though emerging data suggest this may be overly restrictive 6, 4, 5
- For ongoing monitoring: Annual assessment of CAD symptoms with stress testing if symptoms develop 1
Alternative Agents for Patients with CAD
When flecainide is contraindicated due to CAD 1, 8:
- First-line: Dronedarone or sotalol (if no heart failure)
- Second-line: Amiodarone (most effective but reserved due to toxicity profile)
- Avoid: All class Ic agents (flecainide, propafenone)
Critical Monitoring Requirements
If flecainide is used (in appropriate candidates without CAD):
- Baseline and post-initiation ECG to monitor PR and QRS prolongation 1
- QRS widening > 25% from baseline increases proarrhythmia risk 1
- Must be combined with AV nodal blocking agent (beta-blocker or calcium channel blocker) to prevent 1:1 AV conduction during atrial flutter 1
- Plasma level monitoring recommended, keeping trough levels below 0.7-1.0 mcg/mL 3
Common Pitfall to Avoid
The most dangerous error is assuming that "stable CAD" or "old MI" is acceptable for flecainide use. Any history of MI or active ischemia is an absolute contraindication 1, 2, 1, 2. The CAST trial's mortality signal was specifically in post-MI patients, and this remains the foundation of current restrictions despite emerging observational data suggesting potential safety in highly selected stable CAD patients without prior MI 6, 4, 5.